Literature DB >> 18035324

B cells in rheumatoid arthritis.

Serena Bugatti1, Veronica Codullo, Roberto Caporali, Carlomaurizio Montecucco.   

Abstract

Though its etiology remains unknown thus far, the role that autoimmune processes play in rheumatoid arthritis (RA) pathogenesis has been widely proven. Given the easier accessibility of humoral components, the first feature of this contribution to be recognized has been the occurrence of the so-called rheumatoid factor in a large proportion of RA patients. This antibody recognizes the Fc portion of human IgG. By investigating RA pathologic processes and also through experimental models where immune complexes play a fundamental role, many other autoantibodies have then come to our knowledge to be associated with the disease. Their presence and persistence implies that clones of autoreactive B cells survive and proliferate in RA patients under a continuous stimulation. Whether this is a mechanism of disease initiation or just an epiphenomenon is still unclear but no doubt exists that autoantibodies represent a very useful tool in both diagnostic and prognostic terms. Being much more than simple autoantibody producers, B cells are able to secrete many important cytokines and to efficiently present antigens to T lymphocytes in the synovial environment. All of these functions are essential in the development of RA, and lately have claimed attention as B cell depletion has become a common and effective strategy of treatment in RA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18035324     DOI: 10.1016/j.autrev.2007.02.017

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  22 in total

1.  Therapeutic effects of TACI-Ig on rat with adjuvant arthritis.

Authors:  D Wang; Y Chang; Y Wu; L Zhang; S Yan; G Xie; Q Qin; J Jin; W Wang; J Fang; W Wei
Journal:  Clin Exp Immunol       Date:  2010-12-13       Impact factor: 4.330

2.  Suppression of antibody-mediated arthritis in mice by Fab fragments of the mediating antibodies.

Authors:  S Yoshino; M Sasahara; Pilaiwanwadee Hutamekalin; K Yamaki; N Mizutani; H Kuramoto
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 3.  BH3-only proteins in rheumatoid arthritis: potential targets for therapeutic intervention.

Authors:  J Hutcheson; H Perlman
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

Review 4.  Mechanisms of tissue damage in arthritis.

Authors:  Stephan Blüml; Kurt Redlich; Josef S Smolen
Journal:  Semin Immunopathol       Date:  2014-09-12       Impact factor: 9.623

5.  Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19.

Authors:  Dániel Szili; Marcell Cserhalmi; Zsuzsanna Bankó; György Nagy; David E Szymkowski; Gabriella Sármay
Journal:  MAbs       Date:  2014-04-23       Impact factor: 5.857

6.  Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.

Authors:  Kamal D Puri; Michael R Gold
Journal:  Front Immunol       Date:  2012-08-23       Impact factor: 7.561

Review 7.  Osteoimmunology and osteoporosis.

Authors:  Piet Geusens; Willem F Lems
Journal:  Arthritis Res Ther       Date:  2011-09-30       Impact factor: 5.156

Review 8.  Autoantibodies to posttranslational modifications in rheumatoid arthritis.

Authors:  Agata N Burska; Laura Hunt; Marjorie Boissinot; Rocky Strollo; Brent J Ryan; Ed Vital; Ahuva Nissim; Paul G Winyard; Paul Emery; Frederique Ponchel
Journal:  Mediators Inflamm       Date:  2014-03-23       Impact factor: 4.711

Review 9.  B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers.

Authors:  Serena Bugatti; Barbara Vitolo; Roberto Caporali; Carlomaurizio Montecucco; Antonio Manzo
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

Review 10.  Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs.

Authors:  Ennio Giulio Favalli; Serena Bugatti; Martina Biggioggero; Roberto Caporali
Journal:  Biomed Res Int       Date:  2014-04-16       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.